Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK
Status:
Not yet recruiting
Trial end date:
2024-02-16
Target enrollment:
Participant gender:
Summary
This is an open-label, multiple center, single-arm phase II study to evaluate the safety and
efficacy Pembrolizumab,Bevacizumab in combination with Chemotherapy could improve PFS in
Alectinib Failed ALK-rearranged Advanced Lung Adenocarcinoma with Persistent 5'ALK. The
eligible patients should have Stage IV Adenocarcinoma ALK-rearranged tested by NGS Perisitent
with 5'ALK Failed from first line Alectinib. The patients should meet the physical
requirements to receive Pembrolizumab, Bevacizumab with Chemotherapy. All the patients who
meet these requirements will be enrolled in this study. The eligible patients will be treated
with Pembrolizumab 200 mg intravenously (IV) plus Bevacizumab 15mg/kg+ Pemetrexed
500mg/m2+Carboplatin AUC=4 for up to 4 cycles followed by Pembrolizumab 200mg Q3W+
Bevacizumab 15mg/kg+Pemetrexed 500mg/m2 for up to 31cycles or until disease progression,
intolerable toxicity, or physician or participant decision.